A detailed history of Natixis Advisors, L.P. transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 153,717 shares of ROIV stock, worth $1.87 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
153,717
Previous 141,991 8.26%
Holding current value
$1.87 Million
Previous $1.5 Million 18.27%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$10.17 - $12.5 $119,253 - $146,575
11,726 Added 8.26%
153,717 $1.77 Million
Q2 2024

Aug 01, 2024

BUY
$10.36 - $11.74 $158,300 - $179,387
15,280 Added 12.06%
141,991 $1.5 Million
Q1 2024

Apr 25, 2024

BUY
$9.87 - $11.8 $635,154 - $759,353
64,352 Added 103.2%
126,711 $1.34 Million
Q4 2023

Feb 06, 2024

BUY
$8.38 - $11.58 $522,568 - $722,117
62,359 New
62,359 $699,000

Others Institutions Holding ROIV

About Roivant Sciences Ltd.


  • Ticker ROIV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 704,382,976
  • Market Cap $8.56B
  • Description
  • Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...
More about ROIV
Track This Portfolio

Track Natixis Advisors, L.P. Portfolio

Follow Natixis Advisors, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.